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ABSTRACT
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Cerebral ischemia/reperfusion injury (CI/RI) is a common feature of ischemic stroke, involving a period of
impaired blood supply to the brain, followed by the restoration of cerebral perfusion through medical intervention. Although ischemia and reperfusion brain damage is a complex pathological process with an unclear
physiological mechanism, more attention is currently focused on the neuroinflammatory response of an
ischemia/reperfusion origin, and anti-inflammatory appears to be a potential therapeutic strategy following
ischemic stroke. QiShenYiQi (QSYQ), a component-based Chinese medicine with Qi-tonifying and blood-activating property, has pharmacological actions of anti-inflammatory, antioxidant, mitochondrial protectant, antiapoptosis, and antiplatelet aggregation. We have previously reported that the cardioprotective effect of QSYQ
against ischemia/reperfusion injury is via improvement of mitochondrial functional integrity. In this research
work, we aimed to investigate the possible mechanism involved in the neuroprotection of QSYQ in mice model of
cerebral ischemia/reperfusion injury based on the inflammatory pathway. The cerebral protection was evaluated
in the stroke mice after 24 h reperfusion by assessing the neurological deficit, cerebral infarction, brain edema,
BBB functionality, and via histopathological assessment. TCM-based network pharmacology method was performed to establish and analyze compound-target-disease & function-pathway network so as to find the possible
mechanism linking to the role of QSYQ in CI/RI. In addition, RT-qPCR was used to verify the accuracy of
predicted signaling gene expression. As a result, improvement of neurological outcome, reduction of infarct
volume and brain edema, a decrease in BBB disruption, and amelioration of histopathological alteration were
observed in mice pretreated with QSYQ after experimental stroke surgery. Network pharmacology analysis revealed neuroinflammatory response was associated with the action of QSYQ in CI/RI. RT-qPCR data showed that
the mice pretreated with QSYQ could significantly decrease IFNG-γ, IL-6, TNF-α, NF-κB p65, and TLR-4 mRNA
levels and increase TGF-β1 mRNA level in the brain compared to the untreated mice after CI/RI (p < 0.05). In
conclusion, our study indicated the cerebral protective effect of pretreatment with QSYQ against CI/RI, which
may be partly related to its potential to the reduction of neuroinflammatory response in a stroke subject.

Abbreviations: QSYQ, QishenYiqi; CI/RI, cerebral ischemia/reperfusion injury; ASCVD, atherosclerotic cardiovascular disease; CVDs, cardiovascular diseases; TCM,
traditional Chinese medicine; MCAO, middle cerebral artery occlusion; CCA, common carotid artery; ECA, external carotid artery; ICA, internal carotid artery; BBB,
blood-brain barrier; EB, Evans Blue; TTC, 2,3,5-triphenyl-2H-tetrazolium chloride; H&E, hematoxylin & eosin; IFNG-γ, interferon-γ; IL-1, interleukin-1; IL-6,
Interleukin-6; TNF-α, Tumor necrosis factor-alpha; NF-κB, nuclear factor κB; TLRs, Toll-like receptors; ROS, reactive oxygen species; HSPs, heat-shock proteins;
HMGB1, high mobility group box 1; NO, nitric oxide; MMPs, matrix metalloproteinases
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1. Introduction

pathogenesis of CI/RI, anti-inflammation appears to be a potential
therapeutic strategy for neuroinflammatory injury after ischemic stroke
[31]. Neuroinflammatory reactions are mediated by the production of
several crucial cytokines, chemokines, secondary messengers (NO),
reactive oxygen species (ROS) and matrix metalloproteinases (MMPs)
[32]. Many of these mediators are produced by resident immune cells
(including microglia and astrocytes) of the central nervous system,
endothelial cells, and peripherally derived immune cells [33]. Among
these inflammatory mediators, three major pro-inflammatory cytokines: interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are highly concerned because of their influence on neuroinflammatory response [34].
Alternatively, transforming growth factor-β1 (TGF-β1), as an accepted anti-inflammatory cytokine, can suppress the levels of pro-inflammatory cytokines thereby inhibiting inflammation and ischemic
damage [35]. Nuclear factor κB (NF-κB), a typical transcription factor,
is largely associated with the activation of inflammatory responses
[36]. It has been reported that down-regulation of pro-inflammatory
cytokines expression via reducing NF-κB p65 signaling could attenuate
brain damage induced by experimental stroke [37]. Besides, toll-like
receptor 4 (TLR4) also plays a vital role in CI/RI, and the reduction of
TLR4-mediated neuroinflammation can exert a protective effect on
brain damage caused by ischemia/reperfusion [38].
Based on the previous investigations, we proposed that QSYQ may
also contribute to cerebral protection in addition to its known role in
cardioprotection. In the present study, we aimed to test our hypothesis
that pretreatment of QSYQ is beneficial to protect against focal ischemic stroke in mouse model of CI/RI. TCM-based pharmacology
network and experimental verification combination method was performed to decipher the potential link between QSYQ and neuroinflammation in response to CI/RI.

According to the 2019 update of heart disease and stroke statistics
by American Heart Association (AHA), ischemic stroke is still one of the
leading causes of death and serious long-term disability worldwide [1].
At present, intravenous thrombolysis and intra-arterial thrombectomy
are the standard clinical treatment strategies for patients with acute
ischemic stroke [1,2]. Although recombinant tissue plasminogen activator (rt-PA, alteplase) is well-documented for its effect on improving
the prognosis of acute ischemic stroke, the relatively narrow therapeutic time window and a severe hemorrhagic risk limit its further
clinical application [3,4]. Meanwhile, the experienced stroke centers
and qualified neurointerventional doctors are indispensable to operate
rapid mechanical thrombectomy [5]. Moreover, even though restoration of the blood supply by reperfusion can reduce the infarct size and
tissue dysfunction caused by ischemia, rapid reperfusion may also result in a more deleterious effect on functional outcomes [6]. There is no
doubt that cerebral ischemia/reperfusion injury (CI/RI) has become an
increasingly critical challenge for a stroke patient [7]. Up to date, a
series of researches indicated that the main underlying mechanisms of
CI/RI included inflammatory response, oxidative/nitrosative stress,
mitochondrial dysfunction, calcium overload, activation of apoptotic
and autophagic pathways, platelet activation and aggregation, leukocyte infiltration, and complement activation [8–12]. Due to the complicated pathological processes of cerebral ischemia/reperfusion, current therapeutic strategies have not achieved the expected effects.
Therefore, seeking novel and alternative therapeutics for patients with
acute ischemic stroke is still a significant task worldwide.
In China, traditional Chinese medicine (TCM), especially compound
TCM preparations, has been widely applied in clinic for the treatment of
stroke for thousands of years [13]. Based on the theory of TCM, “Qi
deficiency and blood stasis” is one of the primary pathogenesis characteristics of ischemic stroke, compound TCM preparations, which belong to tonifying Qi and activating blood, can protect against CI/RI via
effecting on multiple targets and multiple pathways [14]. Qishen Yiqi
(QSYQ) formula, which is composed of Astragalus membranaceus
(Huangqi), Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi)
and Dalbergia odorifera (Jiangxiang), exerts the function of Qi-tonifying and blood-activating. QSYQ dripping pills is a typical representative of component-based Chinese medicine, which comprises
standard extracts from the above four Chinese herbal medicine, approved by the State Food and Drug Administration of China in 2003.
QSYQ formula and its dripping pill have been widely used in the clinic
to treat cardiovascular diseases (CVDs), including angina pectoris of
coronary heart disease origin with Qi deficiency and blood stasis syndrome [15], and secondary prevention of myocardial infarction [16].
Pharmacological studies have reported that QSYQ is capable of cardioprotection against ischemia/reperfusion injury via regulation of energy metabolism, reduction of oxidative stress and inflammation, as
well as prevention of apoptosis and excessive autophagy [17,18]. Additionally, we have further found the major bioactive ingredients in
QSYQ, such as Astragaloside IV, Calycosin, Ginsenoside Rg1, Ginsenoside Rb1, Notoginsenoside R1, Salvianolic acid A, Salvianolic acid B,
and Tanshinone IIA [19,20]. Interestingly, a series of literatures have
also reported that the above active components of QSYQ had the potential to protect brain from ischemia/reperfusion injury via multifunctional mechanisms [21–28] (details summarized in Supplemental
Table S1). Besides, a recent study by Han and co-workers reported that
T541, which is a compound medicine consisting of total Astragalus
saponins, total salvianolic acids, and total Panax notoginseng saponins,
could exert the function of protecting the integrity of blood-brain barrier (BBB) [29]. These findings imply that in addition to its known role
in cardioprotection, QSYQ may also play a role in cerebral protection in
a specific pathological setting.
Neuroinflammation is defined as an inflammatory response within
the brain or spinal cord [30]. Since it contributes prominently to the

2. Materials and methods
2.1. Drugs and regents
QiShenYiQi (QSYQ) (NMPN Z20030139) was obtained from Tasly
Pharmaceutical Group Co., Ltd. (Tianjin, China), which was prepared
from water-ethanol extracts of Astragalus membranaceus (Huangqi),
Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi) and volatile
oils from Dalbergia odorifera (Jiangxiang) by water extraction and
distillation. QSYQ formula (Huangqi: Danshen:Sanqi: Jiangxiang
oil = 148.01:70.35:70.35:11.97) was prepared and dissolved in ultrapure water to make a solution at concentrations of 5.69 mg/mL,
11.38 mg/mL and 22.75 mg/mL for experiments. Edaravone injection
(drug approval number: H20031342) was purchased from Nanjing
Xiansheng Dongyuan Pharmaceutical Co., Ltd. (Nanjing, China). TTC
(2, 3, 5-Triphenyl-2H-Tetrazolium Chloride) was purchased from
Solarbio (T8170−5 g, Beijing, China). Evans Blue was purchased from
Solarbio (E8010−1 g, Beijing, China). Paraformaldehyde (4 %) was
purchased from Solarbio (P1110−500 mL, Beijing, China. Isoflurane
Lot No. B506 was purchased from Ruiwode Lifescience Co., Ltd.
Shenzhen, China. Omnipaque 300 mg I/mL, drug approval number:
H20000595, Batch No. 12,596,129 was purchased from GE
Pharmaceutical Shanghai Co., Ltd. Shanghai, China. TRIzol® reagent
was obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham,
MA, USA). Transcriptor First Strand cDNA Synthesis Kit was obtained
from Roche (Mannheim, Germany). Bestar®Sybr Green qPCR Master
Mix was obtained from DBI®Bioscience (Ludwigshafen, Germany).
2.2. Ethical use of the laboratory animal
Male 6-week-old Institute of Cancer Research (ICR) mice (22 ± 2 g)
were purchased from Beijing Vital River Lab Animal Technology Co.
Ltd. (Beijing, China, Certificate No.: SCXK Jing 2014-0013). This study
was performed in accord with the recommendations by the Ministry of
2
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Science and Technology of China’s Guidance for the Care and Use of
Laboratory Animals. The protocol approved by the Laboratory Animal
Ethics Committee of Tianjin University of TCM (Permit Number: TCMLAEC2016034 and TJU20160024). The animals were housed in cages
with an ambient temperature of 22 ± 2 °C and humidity of 40 ± 5 %,
under a 12 h light/dark cycle, standard mouse’s chow and water were
provided ad libitum. Animals were fasted for 12 h before the surgery
and provided with free access to water only. The mice were also randomized into several groups. The experimental procedures were in
accord with the European Union (EU) adopted Directive 2010/63/EU.
All animal experiments were carried out following the guidelines of
Tianjin University of TCM Animal Research Committee (TCMLAEC2016034) and approved by the animal care and use committee of
Tianjin International Joint Academy of Biotechnology (No.
TJU20160021). Efforts were made to minimize the number of animals
used and the suffering of experimental animals.

contralateral side); score 3, severe focal neurological deficit (falling to
the contralateral side); score 4, unable to walk spontaneously with a
depressed level of consciousness or death.
2.6. TTC staining and measurement of cerebral infarct
After 24 h reperfusion, the mice were euthanized following anesthetization. Then, the brains were quickly removed and freshly dissected into coronal slices (five 2 mm-thick, n = 6 for each group) in a
rodent brain matrix. Subsequently, the cerebral slices were stained with
2 % TTC solution in the dark for 15 min at 37 °C. White infarct area in
brain tissue was distinguished from red non-infarct area. Stained brain
slices were photographed, and cerebral infarct area was calculated
using ImageJ image processing software (ImageJ 1.42, Wayne Rasband,
National Institutes of Health, United States). Ratios of infarct volume,
which revealed the severity of CI/RI, was presented as a percentage (%)
of (total cerebral infarct volume/total brain volume) × 100. Total infarct volume for each brain was calculated as summation of the infarcted areas of all brain slices (area of infarct in square millimeters × thickness [2 mm]) from the same hemisphere [43].

2.3. Animal grouping and drug administration
Mice were divided into six different groups, including Sham, I/R,
Positive control, QSYQ low dose (5.69 mg/mL)+I/R, middle dose
(11.38 mg/mL)+I/R, and high dose (22.75 mg/mL)+I/R groups.
Seven days before I/R surgery, the mice in treatment groups were orally
administered with QSYQ in ultrapure water once daily for 7 days.
Positive control drug-edaravone (2 mg/mL) was administered via intravenous injection once after 50 min of ischemia. Animals in shamoperated and I/R model groups received 0.9 % normal saline via gavage
at the dose of 10 mL/kg for 7 days.

2.7. Assessment of brain edema via micro-CT scan
Anesthetized mice were intra-arterially injected with 0.5 mL CT
contrast agent (Omnipaque) over a period of 15 s, at 24 h post-reperfusion. Then, the mouse brain was imaged with a small animal
micro-CT imager (Quantum FX; PerkinElmer, United States) with the
following main imaging parameters: voltage for 90 kV, current for
180 μA, field of view (FOV) for 20 mm, and scan for 4.5 min. The 3D
reconstruction of whole-cerebral slide images was performed using
“VOL EDIT” module in Analyze 12.0 image analysis software (Analyze
Direct, Overland Park, KS, USA). Next, the ROI measure module of
software was used to calculate the volumes of the left and right cerebral
hemisphere respectively. According to the left cerebral hemisphere
volume as well as the ratio of the bilateral cerebral hemisphere (left
cerebral hemisphere volume/right cerebral hemisphere volume), we
can indirectly evaluate the severity of cerebral edema. Using the ratio of
the bilateral cerebral hemisphere volume, the degree of the cerebral
edema is evaluated.

2.4. MCAO surgical procedure
Surgery was executed by transient middle cerebral artery occlusion
(tMCAO) technique as described elsewhere [39–41]. In brief, anesthesia
was administered with 4 % isoflurane inhalation and then maintained
with 1.5 % isoflurane in 70 % nitrous oxide (N2O)/30 % oxygen (O2)
with the help of a laboratory anesthesia system (Matrix VIP 3000;
Midmark, USA). We put a drop of ophthalmic lubricant on each eye
using a sterile swab to prevent them from drying during the procedure.
After shaving and swabbing the incision area with 70 % ethanol, the
animal was placed on a warm surgical surface under a stereomicroscope. Then we performed a shallow midline incision in the neck and
carefully separated fatty and connective tissue to expose the trachea.
We exposed the left common carotid artery (CCA) without damaging
nerves and major veins bundled with the CCA, followed by exposing the
top "Y" branching at the external cerebral artery (ECA) and the internal
cerebral artery (ICA). A silicone-coated 4-0 nylon monofilament
(Guangzhou Jialing Biotechnology Co., Ltd., Guangzhou, China) was
inserted into the CCA and gently advanced through the ICA until its tip
occluded the origin of the middle cerebral artery (MCA). Cerebral blood
flow was monitored using PeriFlux System 5000 during MCA occlusion,
and regional cerebral blood flow dropped to 20 % of baseline was recorded. For regaining reperfusion, the monofilament suture was carefully withdrawn after 60 min MCAO. Animals with complications such
as excessive bleeding, filament displacement into the pterygopalatine
artery, died during or less than 24 h after surgery, were excluded from
the experiment.

2.8. Evaluation of the blood-brain barrier Integrity
The integrity Blood-Brain Barrier (BBB) was assessed by Evans Blue
(EB) stain and fluorescent imaging detection using Caliper IVIS Lumina
K Series III system [44]. Briefly, the mice were injected with 0.6 % EB
solution in 0.9 % normal saline (30 mL/kg) via tail vein under anesthesia at the beginning of reperfusion. After 24 h reperfusion, the
animals were intracardially perfusion under deep anesthesia with 0.9 %
normal saline to wash intravascular EB dye away from the circulation.
The brains were excised and placed in the matrix for 2 mm-thick coronal slices as well as photographed to record the EB stained cerebral
sections. Then, Living Image® Software (version 4.3.1) was used to
quantify the concentrations of EB dye leakage according to the value of
total radiant efficiency ([p/s]/[μW/cm2]).
2.9. Hematoxylin & Eosin staining

2.5. Neurological deficit score

In order to observe the histopathological alterations in brain tissues
of different groups, Hematoxylin & Eosin (H&E) analysis was conducted. After 24 h reperfusion, the mice were euthanized following
anesthetization. Brains were quickly removed and cut into coronal
slices and fixed in 4 % paraformaldehyde for 24 h, and then dehydrated
and embedded in paraffin blocks to be dissected into 5 μm coronal
sections. Subsequently, sections were deparaffinized, hydrated with
graded levels of alcohol and stained with H&E using the automatic
dyeing machine (Gemini, Thermo Ltd., United States). Then, the

Examination of neurological deficits of the experimental animals
was performed after 24 h reperfusion. The neurological deficits were
blindly scored on a five-point scale described previously by Longa et al.
[42] with a minor modification: score 0, no neurological deficit
(showing normal and spontaneous movements); score 1, mild focal
neurological deficit (failure to fully extend contralateral forelimb);
score 2, moderate focal neurological deficit (repetitive circling to the
3
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Table 1
Primer sequences for qPCR.
Primer name

Forward primer (5′–3′)

Reverse primer (5′–3′)

qMouse
qMouse
qMouse
qMouse
qMouse
qMouse
qMouse
qMouse

ATGAACGCTACACACTGCATC
GCAACTGTTCCTGAACTCAACT
TAGTCCTTCCTACCCCAATTTCC
CCCTCACACTCAGATCATCTTCT
AGGCTTCTGGGCCTTATGTG
CTCCCGTGGCTTCTAGTGC
ATGGCATGGCTTACACCACC
TGGTGAAGCAGGCATCTGAG

CCATCCTTTTGCCAGTTCCTC
ATCTTTTGGGGTCCGTCAACT
TTGGTCCTTAGCCACTCCTTC
GCTACGACGTGGGCTACAG
TGCTTCTCTCGCCAGGAATAC
GCCTTAGTTTGGACAGGATCTG
GAGGCCAATTTTGTCTCCACA
TGCTGTTGAAGTCGCAGGAG

Ifng
Il1b
Il6
Tnf
Rela
Tgfb1
Tlr4
Gapdh

automatic sealing machine (ClearVue, Thermo, Ltd., United States) was
used to mount the sections. H&E stained images were photographed
using an inverted microscope with 100X and 200X magnification
(CKX41; Olympus, Japan).

2.11. RT-qPCR verification
Brain samples from different groups were collected from the ischemic hemispheres of mice after 24 h reperfusion, snap-frozen in liquid nitrogen and stored at −80 °C until use. The expressions of predicted following core genes: IFNG (IFNG-γ), IL1B (IL-1β), IL6 (IL-6),
TNF (TNF-α), RELA (NF-κB p65), TGFB1 (TGF-β1), and TLR4 (TLR-4)
were validated by reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR). Total RNA samples from the brain
tissues were extracted using TRIzol® reagent (Invitrogen, Thermo Fisher
Scientific, Inc., Waltham, MA, USA) according to the manufacturer’s
protocol. Subsequently, RNA samples were reverse transcribed into
complementary DNA (cDNA) using Transcriptor First Strand cDNA
Synthesis Kit (Roche, Mannheim, Germany) to acquire cDNA. The
Bestar®Sybr Green qPCR Master Mix (DBI®Bioscience, Ludwigshafen,
Germany) was used in RT-qPCR to quantify the level of expression of
the target genes with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as an endogenous reference gene. The gene-specific primers
were synthesized by Sangon Biotech (Shanghai, China) and primer sequences were described in the following Table 1.
The amplification and analysis were performed using
LightCycler®480 Software Version1.5.0.39 (Roche, Mannheim,
Germany) for 45 cycles. The relative mRNA expression levels of predicted key genes were calculated using2−ΔΔCTmethod, following normalization to the housekeeping gene GAPDH.

2.10. Network pharmacology analyses
2.10.1. Database construction
The main source of diseases related targets for CI/RI was collected
from IPA (http://www.ingenuity.com) database [45,46]. Additional
databases, such as OMIM [47], NCBI (gene) [48], TCMSP [49], CAD
Gene [50], GeneCards [51], MalaCards [52] and PubMed, were
manually searched to replenish the omissive diseases-related targets of
IPA. Information on QSYQ (Huangqi, Danshen, Sanqi and Jiangxiang)
ingredients were obtained from several online TCM databases, including TCMSP [53], TCMID [54], TCM-ID [55], TCM Database@Taiwan [56], TCMGeneDIT [57] and BATMAN-TCM [58]. PubChem
[59] was also used to retrieve and verify ingredients of TCM. Literature
mining based on PubMed was indispensable [60–62]. Since TCM ingredients-gene targets relationship were limited in IPA database, additional NCBI (gene) [48], TCMSP [49], TCMID [50], PubChem [59]
and PubMed were also mined to supplement QSYQ ingredients corresponding targets. Details including web links to the databases were
shown in Supplemental Table S2.
2.10.2. Network establishment and analysis
Three datasets, ① Cerebral I/R injury-related targets, ② Huangqi,
Danshen, Sanqi and Jiangxiang ingredients, and ③ QSYQ major ingredients and their corresponding targets, were constructed and imported into IPA system for data visualization and detailed analysis.
Specifically, ① CI/RI relevant targets as well as the relationship between
QSYQ (Huangqi, Danshen, Sanqi and Jiangxiang) components and the
diseases related targets were discovered via employing “Build-Path
Explorer” module,②“Build-Grow-Diseases& Functions” module was
applied to uncover diseases and functions that corresponding targets of
QSYQ major ingredients involved in, ③the canonical pathways, which
corresponding targets of QSYQ major ingredients referred to, were
generated by using “Overlay-Canonical Pathway” module. Ultimately,
an integrated compound-target-disease & function-pathway network
was established. In order to further acquire the correlation degree between corresponding targets of QSYQ major ingredients and diseases,
functions as well as pathways, “Core analysis” module was performed
to analyze the above network. Apart from acquisition of top diseases,
top functions and top pathways, “Core Analysis-Upstream Analysis”
module was employed to obtain top upstream regulators so as to illuminate the causal inference of upstream biological causes and probable
downstream effects on cellular and organismal biology [63]. “BuildConnection” module was used to show the interactive relationship of
targets-targets and gain the core targets among QSYQ major ingredients
corresponding targets based on the significance of targets in interaction
network. “Path designer” module was used to polish the network
images and graphs. The algorithm of the network analysis was based on
Fisher’s exact test with the enrichment score of P-values.

2.12. Statistical analysis
Data from different experiments were presented as mean ± SD as
indicated. Statistical analysis was carried out using Student’s two-tailed
t-test for comparison between two groups and using one-way analysis of
variance (ANOVA) followed by Dunnett’s t-test for comparisons between multiple groups. For the neurological deficit score, data were
presented as median and nonparametric statistical analysis was used
using Mann-Whitney test for comparison between two groups. p <
0.05 was defined as statistically significant and p < 0.01 was regarded
to be highly significant. All data graphs were generated by GraphPad
Prism 7 software (GraphPad Software, Inc., La Jolla, CA, United States).
3. Results
A combined pharmacology network analysis and experimental
verification approach were established in this study, to further reveal
the action mechanisms of QSYQ in CI/RI, which involves five steps in a
workflow shown in Fig. 1: (1) efficacy of a prescription (QSYQ) in
preventing CI/RI was determined with several typical indicators; (2)
ingredients of the prescription along with their corresponding diseases
associated targets were identified by mining various databases; (3) the
relationship between compound-target-pathway-disease & function
were constructed by interaction networks and top diseases & functions
and top canonical pathways were uncovered by network analysis; (4)
key targets were determined via integrating upstream analysis, inflammatory response and neuroinflammation signaling pathway; (5)
4
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Fig. 1. Workflow for cerebral protective effect of QSYQ in a CI/RI model.
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Fig. 2. QSYQ pretreatment ameliorated neurological deficit and brain infarction. (A) Effects of QSYQ on the neurological deficit score. QSYQ/edaravone pretreatment obviously improved the neurological deficit score (n＝12). (B) Representative images of TTC-stained brain sections of each group. The infarct areas were
colored white, whereas normal areas presented a red color. (C) Quantitative analysis of cerebral infarction volumes of each group (n＝6). QSYQ/edaravone pretreatment significantly reduced the infarct volumes. Neurological deficit score data are reported as the median and TTC staining data are reported as the
means ± SD. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus the sham group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus the model group. I/R,
ischemia/reperfusion; edaravone; QSYQ-L, 5.69 mg/mL (low dose); QSYQ-M, 11.38 mg/mL (middle dose); QSYQ-H, 22.75 mg/mL (high dose).

the possible mechanism of the prescription in cerebral protection was
validated, and the accuracy of network analysis was guaranteed by
experimental verification.

also significantly reduced the infarction volumes of MCAO mice [(F (4,
25) = 21.606, p = 0.000)].
3.3. QSYQ pretreatment attenuated cerebral edema

3.1. QSYQ pretreatment ameliorated neurological deficits

Next, we performed a micro-CT scan to acquire the whole-cerebral
slide images and estimated the severity of cerebral edema in different
treatment groups using Analyze 12.0 image analysis software. The results of the representative coronal image in each group were shown in
Fig. 3A. When the offset distance of midline in the cerebral coronal
image was compared, the most obvious midline offset, caused by cerebral edema, was observed in the model group. On the other hand,
similar to that of positive drug edaravone, pretreatment with different
doses of QSYQ also reduced midline offset. 3D reconstruction of wholecerebral slide images (flow diagram shown in Fig. 3B) and quantitation
of the bilateral cerebral hemisphere volume were realized. The value of
left cerebral hemisphere volume and statistical data were shown in
Fig. 3C, meanwhile, the value of the ratio of the bilateral cerebral
hemisphere volume and statistical data were shown in Fig. 3D. Compared with the sham group, left cerebral hemisphere volume and the
ratio of the bilateral cerebral hemisphere volume increased because of
suffering from left MCAO surgical operation (F = 2.353,t=-3.275,
p = 0.011;F = 14.776, t=-10.472, p = 0.000).However, pretreatment
with edaravone obviously decreased left cerebral hemisphere volume [F
(4,20) = 2.504, p = 0.027 vs. model] and the ratio of the bilateral
cerebral hemisphere volume [F(4,20) = 21.530, p = 0.000 vs. model].Surprisingly, pretreatment with QSYQ dose-dependently reduced
the ratio of the bilateral cerebral hemisphere volume [from
1.365 ± 0.06507 to 1.266 ± 0.06052, F(4,20) = 21.530, p = 0.012 vs.
model; 1.247 ± 0.02491, F(4,20) = 21.530, p = 0.003 vs. model; and
1.171 ± 0.04540, F(4,20) = 21.530, p = 0.000
vs. model]. Besides, pretreatment with QSYQ could also reduce the
value of left cerebral hemisphere volume of MCAO mice to some extent,
but did not reach significance [F(4,20) = 2.504, p > 0.05 vs.
model].In conclusion, the left cerebral hemisphere volume as well as

In order to assess the protective effect of QSYQ on neurological
deficits, we made the transient MCAO (1 h occlusion followed by 24 h
reperfusion) and a pretreatment regimen. The criterion of Longa’s score
was adopted to estimate neurological deficits. As shown in Fig. 2A, mice
subjected to sham operation moved normally without neurological
deficit symptoms. However, cerebral ischemia strongly altered neural
behavior of mice in the model group as indicated by the highest neurological deficit score among six groups. Compared with the model
group, pretreatment with a positive-control drug edaravone significantly decreased neurological deficit score with better neural behavior (p = 0.005). Meanwhile, mice pretreated with QSYQ at a middle
dose (11.38 mg/mL) and high dose (22.75 mg/mL) also significantly
reduced neurological deficit score compared with the MCAO mice in
model group (p = 0.046 and p = 0.021).
3.2. QSYQ pretreatment reduced cerebral infarction volume
In addition to the neurological deficit score, the cerebral protective
effects of QSYQ pretreatment were assessed with regards to infarction
volume in MCAO mice by using TTC staining. The representative TTCstained cerebral slices in each group were shown in Fig. 2B, and the
corresponding infarction volumes and statistical data were shown in
Fig. 2C. As expected, mice in the sham group exhibited no infarction.
Conversely, the transient MCAO model group showed obviously increased infarct volume (37.66 ± 3.10 % of the cerebral volume).
Compared with the model group, the positive control group (edaravone
at a dose of 9 mL/kg) significantly inhibited I/R-induced infarction [F
(4, 25) = 21.606, p = 0.000)]. At the same time, pretreatment with
QSYQ at a middle dose (11.38 mg/mL) and high dose (22.75 mg/mL)
6
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Fig. 3. QSYQ pretreatment reduced the cerebral edema caused by CI/RI. (A) Representative pictures of cerebral coronal images from each group mice. yellow line
used to ensure the cerebral midline and red arrow used to indicate offset distance of midline. (B) The flow diagram to display the brief process about how to realize
3D reestablishment and quantization of brain hemisphere. (C)Quantitative analysis of left cerebral hemisphere volume from each group mice. Edaravone pretreatment significantly stopped higher values of left cerebral hemisphere volume caused by cerebral edema compared with the model mice. (D)Quantitative analysis
of the ratio of bilateral brain hemisphere volume from each group mice. Pretreatment with QSYQ dose-dependently decreased the raised values of the ratio of
bilateral brain hemisphere volume because of left MCAO surgical operation compared with the model mice. Data are expressed as mean ± SD. #p < 0.05, ##p <
0.01, and ###p < 0.001 versus the sham group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus the model group, n＝5. I/R, ischemia/reperfusion; Eda,
edaravone; QSYQ-L, 5.69 mg/mL (low dose); QSYQ-M, 11.38 mg/mL (middle dose); QSYQ-H, 22.75 mg/mL (high dose).

the ratio of the bilateral cerebral hemisphere volume could indirectly
reveal the severity of cerebral edema. QSYQ pretreatment attenuated
cerebral edema in MCAO mice.

and uniformly arranged, exhibiting a normal structural form: the cell
outline was clear, the normal morphology was intact, and the nucleolus
was clearly visible. However, ischemia /reperfusion caused severe damage to the cerebral tissues/cells. Numerous vacuolated spaces were
seen in brain tissues. The cells became sparse and disorderly-arranged,
the neurons were swollen or shrunken, and the nucleolus disappeared.
Compared with the model group, pretreatment with different dosage of
QSYQ as well as edaravone could relieve the pathological abnormalities
caused by CI/RI at a certain degree.

3.4. QSYQ pretreatment reduced BBB disruption in MCAO mice
It is known to us that BBB breakdown is a common pathophysiological feature in CI/RI. Therefore, the protective effect on the integrity
of BBB is a crucial aspect of cerebral protection. As a marker of albumin
effluxion, EB dye is used to estimate BBB permeability. During BBB
disruption after I/R, EB can easily permeate BBB and stain brain tissue
in blue color. Hence, we used EB to investigate whether QSYQ pretreatment could inhibit BBB disruption. Fig. 4A shows the result of EBstained slices. We compared EB leakage in the ipsilateral hemisphere
among all groups. The sham group had intact BBB contrarily to EB
leakage in the MCAO (model) group. In contrast, pretreatment with
QSYQ markedly diminishes the EB extravasation as same as edaravone.
In order to quantify the EB leakage, a rapid and convenient method of
fluorescent imaging mode detection of Caliper IVIS Lumina K Series III
was employed. The representative fluorescent images in each group are
shown in Fig. 4B. The corresponding value of total radiant efficiency
and statistical data are shown in Fig. 4C. Compared with the sham
group, the MCAO caused serious disruption of BBB in the model
(F = 10.353, t=-8.737, p = 0.000).As expected, pretreatment with
edaravone significantly decreased EB extravasation [F(4,20) = 13.996,
p = 0.000 vs. model].Interestingly, pretreatment with QSYQ dose-dependently reduced EB leakage [from 2.10E9 ± 4.53E8 to
1.48E9 ± 3.31E8 [p/s]/ [μW/cm2], [F(4,20) = 13.996, p = 0.007 vs.
model; 1.29E9 ± 1.80E8 [p/s]/ [μW/cm2],
[F(4,20) = 13.996, p = 0.001 vs. model; and 1.05E9 ± 9.28E7 [p/
s]/ [μW/cm2], [F(4,20) = 13.996, p = 0.000 vs. model].

3.6. Identification of target-disease & function-pathway of QSYQ
components in prevention and treatment for CI/RI
Among the total of 452 CI/RI-related targets recognized in
Ingenuity Pathway Analysis (IPA, Supplemental Table S3), 220 of them
(48.7 %) were found to be associated with QSYQ ingredients (Huangqi,
Danshen, Sanqi, Jiangxiang, and QSYQ). To decipher the multi-target
pharmacological mechanisms of QSYQ in prevention and treatment for
CI/RI, compound-target combined with target-disease & functionpathway networks were established. Firstly, a fifty-five QSYQ ingredient network was established, which comprised fourteen Huangqi
compounds, fifteen Sanqi compounds, twenty Danshen compounds, and
six Jiangxiang compounds. modulated the two hundred and twenty CI/
RI related targets. In order to display the possible cellular locations and
multi-target biological processes of QSYQ ingredients, we integrated
the compound-target network according to extracellular space, plasma
membrane, cytoplasm, and nucleus. Meanwhile, the characteristic of
traditional Chinese medicine in prevention and treatment diseases
through the multidimensional interactions between multiple ingredients and multiple targets was visually presented in Fig. 6A. Secondly, with the intention of clarifying the main biological processes and
molecular mechanisms of QSYQ acting on the 220 CI/RI related targets,
an integrated target-disease & function-pathway network containing
the most associative diseases, most correlative functions, and the most
interrelated pathways were built via taking reasonable advantage of
various distinctive modules of IPA, such as “Core Analysis”, “Canonical
Pathway”, “Diseases & Functions”, and so on. Based on the Fisher’s

3.5. Histopathological assessment of QSYQ pretreatment on mice brain
As shown in Fig. 5, the cerebral tissues/cells in the sham operation
group were normal. The brain tissues remain undamaged, and no obvious vacuolated spaces were observed. The nerve cells were densely
7
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Fig. 4. QSYQ pretreatment protected the BBB integrity against stroke-related damage. (A) Representative pictures of coronal slices from each group of the mice brain
stained with EB dye after ischemic-reperfusion. (B) The corresponding fluorescence images of EB extravasation of each group of the mice cerebral coronal sections.
(C) Quantitative analysis of EB leakage of each group of the mice cerebral coronal slices. QSYQ/edaravone pretreatment markedly decreased EB leakage caused by
BBB breakdown compared with the MCAO. Data are expressed as mean ± SD. #p < 0.05, ##p < 0.01, and ###p < 0.001 versus the sham group; *p < 0.05,
**p < 0.01, and ***p < 0.001 versus the model group, n＝5. I/R, ischemia/reperfusion; Eda, edaravone; QSYQ-L, 5.69 mg/mL (low dose); QSYQ-M, 11.38 mg/mL
(middle dose); QSYQ-H, 22.75 mg/mL (high dose).

exact test algorithm of IPA, the diseases, functions, and pathways were
ranked respectively according to corresponding p-value scores so as to
distinguish the relatedness or importance among the 220 targets and
diverse diseases, functions as well as pathways. The most obvious diseases that are affected by QSYQ in the order of descending –log (pvalue) score were, rheumatism, Alzheimer’s, dementia, diabetes mellitus, atherosclerosis, lymphocytic cancer, gastroenteritis, colitis, obesity, and myocardial infarction. Among them, rheumatic ranked the
highest with a –log (p-value) score of 85 (Fig. 6B). At the same time,
QSYQ was predicted to influence multiple functions including, in the

order of descending –log (p-value) score: angiogenesis, leukocyte migration, necrosis, apoptosis, vasculogenesis, inflammatory response,
fibrosis, synthesis of reactive oxygen species, autophagy, and synthesis
of nitric oxide. Among them, the angiogenesis ranked the highest with a
–log (p-value) score of 125 and the inflammatory response ranked the
sixth with a –log (p-value) score of 108 (Fig. 6C). On the basis of the
result of core analysis and canonical pathways analysis aiming at 220
targets, targets-related major pathways were acquired. Neuroinflammation signaling-pathway was considered the most-essential
pathway, with the highest –log (p-value) score of 72 (Fig. 6D).

Fig. 5. Effect of QSYQ pretreatment on pathological changes of the brain cortex after CI/RI (H&E Staining, ×100; scale bar: 100 μm and H&E Staining, ×200; scale
bar: 50 μm) (n = 3). Pretreatment with different dosage of QSYQ as well as edaravone could reduce the histopathological alteration after CI/RI at a certain degree. I/
R, ischemia/reperfusion; Eda, edaravone; QSYQ-L, 5.69 mg/mL (low dose); QSYQ-M, 11.38 mg/mL (middle dose); QSYQ-H, 22.75 mg/mL (high dose).
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Fig. 6. Analysis of QSYQ’s compound-target-disease & function-pathway. (A) QSYQ ingredient-disease related target network. 14 Huangqi compounds (yellow), 15
Sanqi compounds (leaf-green), 20 Danshen compounds (light-blue), and 6 Jiangxiang compounds (pink) were presented, which cooperatively modulated a total of
220 CI/RI related targets. The bottom right corner diagram displayed the unique numbers of ingredients from QSYQ. (B, C, and D) Diseases, functions, and pathways
affected by QSYQ were ranked according to the Fisher’s exact test algorithm. Top 10 diseases, top 10 functions, and top 20 pathways were displayed in descending
order based on –log (p-value) score.
9
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Fig. 7. Determination of key targets
modulated by QSYQ. (A) Upstream network analysis. Top 20 upstream regulators
(red) and their corresponding downstream
targets were shown. (B)135 targets correlated with inflammatory response picked
out from 220 targets regulated by QSYQ
with the help of IPA software. (C)The relationship between inflammatory response-related targets (green) and neuroinflammation signaling pathway-related
targets (blue). The common targets
(yellow) shared by the inflammatory response and neuroinflammation signaling
pathway were displayed. The more important was that 7 core upstream regulators (pink) in line with the common
targets were found. (D) The PPI network
between the seven key upstream regulators. The result of cross-talk proteinprotein interaction (PPI) between the
seven upstream regulators was displayed.
(E) The cooperative actions of 42 QSYQ
ingredients on the seven key upstream
regulators. This sub-network was separated from QSYQ ingredient-target network (Fig. 6B), including 11 Huangqi
(yellow), 15 Danshen (blue),13 Sanqi
(green), and 3 Jiangxiang (pink) components.
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3.7. Determination of QSYQ-modulated target networks in
neuroinflammation

infarct size, BBB breakdown and brain edema induced by experimental
stroke [67,68]. Similar to edaravone, the present study demonstrated
that pretreatment with middle and high dose QSYQ for 7 days significantly decreased CI/RI-induced disability, cerebral infarct volume
and histological damage (Figs. 2 and 5).
The BBB plays vital roles in maintaining homeostatic microenvironment of the central nervous system and effective protection of
brain tissue from outside stimuli [69]. BBB dysfunction, characterized
by structural breakdown of tight junction protein complexes leading to
increased permeability, ion transporter dysfunction causing cerebral
edema, and further inflammatory damage caused by infiltrating leukocytes, is a remarkable pathological characteristic of ischemic stroke
[70]. It is worth noting that ischemia-induced BBB disruption in the
early stages of stroke largely correlates with hemorrhagic transformation following rt-PA thrombolysis treatment [71]. In the present research, luminance imaging and micro-CT were respectively used to
assess the BBB permeability and cerebral edema. The results clearly
showed that pretreatment with QSYQ dose-dependently attenuated the
BBB breakdown and the severity of brain edema caused by ischemia
and reperfusion (Figs. 3 and 4).
It is known that brain damage induced by ischemia and reperfusion
is a complex pathophysiological process with various mechanisms [6].
In recent years, network pharmacology analyses, which illuminate the
synergistic effects and the underlying pharmacological mechanisms of
multicomponent and multitarget agents from TCM formulae, proved to
be a powerful paradigm to provide a better understanding of the underlying intricate relationships between TCM herbal ingredients and
diseases through the bridge “targets” [72–74]. We have previously used
this approach to reveal the endothelial inflammation as a common
mechanism for stroke and coronary artery disease treatment by Danhong injection [45]. In the present study, similar analysis of a more
complex Chinese medicine QSYQ that also contains Danshen (4 vs. 2
herbal components) revealed yet a more complex but still synergistic
compound-target-disease & function-pathway network. We found that
inflammatory response and neuroinflammation signaling pathway were
closely correlative with 220 CI/RI related targets which could be
regulated by the identified ingredients of QSYQ (Fig. 6). This result
suggested that neuroinflammation could account at least in part for
cerebral protection of QSYQ. According to the integration of inflammatory response, neuroinflammation signaling pathway and upstream regulators, we further acquired the core targets associated with
neuroinflammatory response, including IFNG (IFNG-γ), IL1B (IL-1β),
IL6 (IL-6), TNF (TNF-α), RELA (NF-κB p65), TGFB1 (TGF-β1), and TLR4
(TLR-4) (Fig. 7).
Interferon-γ (IFNG-γ), an inflammatory mediator released from
CD4+ and CD8+ T-lymphocytes as well as natural killer (NK) cells, is
considered a crucial regulator of immune and inflammatory responses
after CI/RI [75]. IFNG-γ mRNA expression was elevated in rat brain
after permanent middle cerebral artery occlusion (pMCAO) [76]. A
group of studies revealed the multipotent inflammatory properties of
IFNG-γ that initiated several pathways participated in CI/RI such as
induction of adhesion molecule expression, stimulation of NAD(P)H
oxidase, and activation of microglia-macrophages [77–79]. Interleukin1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha
(TNF-α) are three major pro-inflammatory cytokines, and are generally
considered to be main contributors to acute inflammation in ischemic
stroke [32]. In experimental ischemic stroke, elevated IL-1β level led to
more serious brain edema and brain infarction [80]. Similarly, knockdown of IL-1β could improve pathological changes induced by hypoxia/
ischemia in cell and animal model [81]. IL-6 expression was enhanced
continuously up to 24 h reperfusion after ischemia onset [82]. In acute
ischemic stroke patients, increased IL-6 levels of blood samples and
larger infarct volume as well as less favorable prognosis were reported
[83]. However, ambivalent data on IL-6 also exists. Clark et al. did not
observe smaller lesion size and better neurological function in IL-6
deficient mice after brain ischemia surgery [84]. In ischemic brain

In order to confirm the core targets affected by QSYQ, upstream
genes of the core targets were first determined and the top 20 upstream
regulators and their corresponding targets are shown (Fig. 7A, Supplemental Table S4). Disease & function analysis revealed a close correlation between QSYQ targets and inflammatory response, consistent
with the notion that inflammation as one of the most significant mechanisms involved in the pathogenesis of acute ischemic stroke and CI/
RI. The vital role of inflammatory response in QSYQ protective action
on CI/RI was further demonstrated by separating the 135 inflammation-related targets from the total 220 QSYQ ingredient-interacting
genes (Fig. 7B). The close relationship involved in multiple shared and
unique targets between inflammatory response and neuroinflammation
signaling pathway was also verified in the network (Fig. 7C). Interestingly, 7 targets belong to the top 20 upstream regulators. Among them,
four cytokines, IFNG(IFNG-γ), IL1B (IL-1β), IL6 (IL-6), TNF (TNF-α),
one transcription regulator, RELA (NF-κB p65), one growth factor,
TGFB1 (TGF-β1), and one transmembrane receptor, TLR4 (TLR-4) were
shown to have a cross-talking protein-protein interaction (PPI)
(Fig. 7D). Finally, the 42 QSYQ ingredients synergistically regulating
these seven inflammatory response-related molecules are illustrated
(Fig. 7E). Based on above analysis, these 7 targets were considered as
the most crucial targets in integrated inflammatory response, neuroinflammatory signaling pathway and their upstream regulators and were
chosen for further experimental validation next.
3.8. RT-qPCR validation of QSYQ-modulated targets in neuroinflammation
effects on regulating core targets by QSYQ
To validate the regulatory role of QSYQ on the core inflammatory
targets forecasted above, we compared the expression of the following
genes, IFNG-γ, IL-1β, IL-6, TNF-α, NF-κB p65, TGF-β1, and TLR-4, in
brain samples from cerebral I/R injury model, and model treated with
QSYQ (22.75 mg/mL) by RT-qPCR (Fig. 8). Compared with the I/R
group, the IFNG-γ, IL-6, TNF-α, NF-κB p65, and TLR-4 mRNA levels
were significantly decreased in the QSYQ-treated group (for IFNG-γ,
F = 0.149, p = 0.000; IL-6, F = 1.469, p = 0.000; TNF-α, F = 3.986,
p = 0.000; NF-κB p65, F = 2.203, p = 0.000; TLR-4, F = 0.829,
p = 0.018; Fig. 8A-8E). Meanwhile, an increase in expression of TGF-β1
mRNA was significant in QSYQ-treated group when compared to the
model (F = 0.034, p = 0.002; Fig. 8F). Besides, pretreatment of QSYQ
down-regulated IL-1β mRNA levels to some extent, but did not reach
significance (F = 0.752, p = 0.216; Fig. 8G).
4. Discussion
Ischemic stroke is one of the leading causes of morbidity and mortality in humans.CI/RI is a typical feature of ischemic stroke, which
occurs during the restoration of blood supply after a period of cerebral
vessel occlusion [6]. Nowadays, because of the limitations of rt-PA in
clinical use, more and more compound TCM preparations applied to
treat ischemic stroke with advantage of less side effects and multifunctional pathways [64,65]. QSYQ is one of the representative component-based Chinese medicine to treat CVDs. Since a large clinical trial
approved that QSYQ is effective to reduce thrombotic vascular disease
risk, it has been widely used for the secondary prevention of myocardial
infarction in China [16]. We have previously reported the cardioprotection against ischemia/reperfusion injury by QSYQ and its bioactive
ingredients [19,20]. In this study, the cerebral protective effect of QSYQ
was observed for the first time in experimental mouse model of CI/RI.
Edaravone was chosen as positive drug in this study because of its role
as an antioxidant and hydroxyl radical scavenger to significantly improve the degree of neurological impairment of patients during acute
cerebral infarction [66]. Besides, it has also been shown to reduce
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Fig. 8. Regulation of inflammatory genes by pretreatment with QSYQ in I/R mouse brain. Relative expression levels of cerebral IFNG-γ (A), IL-6 (B), TNF-α (C), NFκB p65 (D), TGF-β1 (E), TLR-4 (F), and IL-1β (G) mRNA were evaluated by RT-qPCR. Results were normalized to GAPDH. Data are expressed as mean ± SD. *p <
0.05, **p < 0.01, and ***p < 0.001 versus I/R group, n＝3. QSYQ-H, 22.75 mg/mL (high dose).

tissues of rats, TNF-α mRNA was upregulated from 3 h to 24 h after
stroke [85]. Brain ischemia also increased TNF-α protein in cerebral
tissue at 6 and 24 h after MCAO [86]. Transforming growth factor-beta
(TGF-β) is thought to play both neuroprotective and anti-inflammatory
roles in stroke [87]. In the acute phase of cerebral ischemia, upregulation of TGF-β can promote regulatory T-cells (Treg cells) development
to produce the anti-inflammatory cytokine IL-10 as well as reduce Th1
and Th2 responses [88]. Ronaldson et al. proved that administration of
exogenous TGF-β1 decreased BBB permeability during inflammatory
pain [89]. Furthermore, overexpression of TGF-β1 could inhibit ischemic brain damage via downregulating the expression of some inflammatory proteins [90].
As a typical transcription factor, nuclear factor κB (NF-κB) is well
known to be activated in CI/RI. Brain samples from postmortem ischemic stroke patients further illustrated higher levels of NF-κB in the
ischemic infarct area and necrotic infarct core [91]. Xiang et al. reported that down-regulation of NF-κB p65 activation involved in selectively modulating microglia M1/M2 polarization so as to play the
anti-inflammatory effect [92]. In addition, prevention of cerebral NF-κB
p65 activation and reduction of inflammation response could contribute to protecting the blood brain-barrier (BBB) as well as to attenuate brain damage induced by ischemia-reperfusion [93]. Among
Toll-like receptors (TLRs) family, accumulating evidence showed the
importance of TLR4 in cerebral ischemic injury. Increased expression of
brain TLR4 was found in both cell and animal models of stroke. Hyakkoku et al. reported that TLR4 knockout mice had significantly smaller
infarct volume and better neurological function compared to wild-type
mice after undergoing brain injury induced by ischemia and reperfusion

[94]. Meanwhile, Caso et al. also observed that TLR4 deficient mice had
minor infractions and less inflammatory response after experimental
stroke [95].
In order to confirm the reliability of network analysis, RT-qPCR was
performed to test the mRNA expressions of neuroinflammation related
targets. Results of the present study showed that the mice pretreated
with QSYQ could significantly decrease IFNG-γ, IL-6, TNF-α, NF-κB
p65, and TLR-4 mRNA levels and increase TGF-β1 mRNA level in brain
tissue compared to the untreated mice after 1 h cerebral ischemia and
24 h reperfusion. Besides, pretreatment of stroke subject with QSYQ
down-regulated IL-1β mRNA levels to some extent, but showed no
significance as compared to the model group. The data suggest that the
beneficial effects of QSYQ pretreatment on brain damage caused by
experimental stroke is partly through reduction of neuroinflammatory
response.
5. Limitation and future directions
Despite of interesting new findings in this study, some limitations
exist. The following directions and prospects should be considered in
future investigation: firstly, our current study mainly used the method
of TCM-based pharmacology network to explore the possible mechanism involved in the neuroprotection of QSYQ in mice model of CI/
RI based on the neuroinflammatory pathway. Furthermore, we did an
extensive gene profiling of the major pharmacological targets which
confirmed the positive therapeutic application of QSYQ in CI/RI. All
these is to some extent, adequate for the present study. Of course,
multiple omics approaches, especially proteomics or transcriptome
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neuroinflammatory related bioactive components in QSYQ [96,97].
Besides, the establishment of BBB organoids vitro model offer us a highthroughput and cost-effective approach to accelerate therapeutic discovery [98]. Maybe we can also employ BBB organoids vitro model to
filtrate the bioactive components in QSYQ. Thirdly, although we focused on neuroinflammatory response as one of the important underlying mechanism of QSYQ against ischemia/reperfusion injury, on the
basis of the properties of multi-components, multi-targets, multiple
therapeutic pathways, the other potential mechanisms, including oxidative stress, production of ROS, synthesis of nitric oxide (NO), mitochondrial function, apoptosis and autophagy, still need more studies
so as to further account for cerebral protection action of QSYQ in acute
ischemic stroke. Meanwhile, according to the present results, it is significant to continue the next research on pharmacodynamic effects of
QSYQ in the subacute and long-term phases of focal CI/RI as well as
their corresponding neuroinflammatory and other underlying mechanisms.
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